 I announce that the Senator from Vermont (Mr. Sanders) is  necessarily absent.    Mr. President, I ask unanimous consent that the text of  the bill be printed in the Record.   There being no objection, the text of the bill was ordered to be  printed in the Record, as follows:                                   S. 551         Be it enacted by the Senate and House of Representatives of       the United States of America in Congress assembled,       SECTION 1. SHORT TITLE.         This Act may be cited as the ``Recovering Excessive Funds       for Unused and Needless Drugs Act of 2019'' or the ``REFUND       Act of 2019''.       SEC. 2. REQUIRING MANUFACTURERS OF CERTAIN SINGLE-DOSE VIAL                     DRUGS PAYABLE UNDER PART B OF THE MEDICARE                     PROGRAM TO PROVIDE REBATES WITH RESPECT TO                     DISCARDED AMOUNTS OF SUCH DRUGS.         (a) In General.--Section 1834 of the Social Security Act       (42 U.S.C. 1395m) is amended by adding at the end the       following new subsection:        ``(w) Rebate for Certain Discarded Single-dose Vial       Drugs.--        ``(1) In general.--The manufacturer (as defined in section       1847A(c)(6)(A)) of a rebatable single-dose vial drug       furnished in a calendar quarter shall, not later than 30 days       after the date of receipt of information described in       paragraph (2)(A)(iii) with respect to such quarter, provide       to the Secretary a rebate that is equal to the amount       specified in paragraph (3) for such drug for such quarter.        ``(2) Secretarial duties.--        ``(A) In general.--For each calendar quarter, the Secretary       shall, with respect to a rebatable single-dose vial drug of a       manufacturer furnished during such quarter--        ``(i) require, through use of a modifier such as the JW       modifier used as of the date of enactment of this subsection       (or any such successor code that includes such data as       determined appropriate by the Secretary), an indication on a       claim for such drug of the amount of such drug that was       discarded after such drug was furnished, if any;        ``(ii) determine the rebatable amount (as defined in       subparagraph (B)) with respect to such drug; and        ``(iii) not later than 60 days after the end of such       quarter, provide to such manufacturer notice of--         ``(I) the total number of units of such drug discarded       during such quarter (as determined by the Secretary based on       the aggregate rebatable amount (as so defined) with respect       to such drug for such quarter), if any; and        ``(II) the rebate amount specified in paragraph (3) for       such drug and such quarter.         ``(B) Rebatable amount.--The term `rebatable amount' means,       with respect to a rebatable single-dose vial drug of a       manufacturer furnished during a quarter, 90 percent of the       amount (if any) of such drug that was discarded as indicated       pursuant to subparagraph (A)(i).        ``(3) Rebate amount.--The amount of the rebate specified in       this paragraph is, with respect to a rebatable single-dose       vial drug of a manufacturer furnished in a calendar quarter,       an amount equal to the product of--        ``(A) the total number of units of such drug discarded       during such quarter as determined under paragraph       (2)(A)(iii)(I); and        ``(B) the lesser of--        ``(i) the average sales price (as defined in section       1847A(c)(1)) for a unit of such drug for such quarter (or, in       the case of a drug subject to an agreement with such       manufacturer under section 340B of the Public Health Service       Act, the price for a unit of such drug for such quarter under       such agreement); or        ``(ii) the wholesale acquisition cost (as defined in       section 1847A(c)(6)(B)) for a unit of such drug.        ``(4) Rebate deposits.--Amounts paid as rebates pursuant to       paragraph (1) shall be deposited into the Federal       Supplementary Medical Insurance Trust Fund established under       section 1841.        ``(5) Enforcement.--        ``(A) Audits.--Each manufacturer of a rebatable single       dose-vial drug that is required to provide a rebate under       this subsection shall be subject to periodic audit with       respect to such drug and such rebates by the Secretary.        ``(B) Civil money penalty.--        ``(i) In general.--The Secretary shall impose a civil money       penalty on a manufacturer of a rebatable single dose-vial       drug who has failed to comply with the requirement under       paragraph (1) for such drug for a calendar quarter in an       amount the Secretary determines is commensurate with the sum       of--         ``(I) the amount that the manufacturer would have paid       under such paragraph with respect to such drug for such       quarter; and        ``(II) 25 percent of such amount.         ``(ii) Application.--The provisions of section 1128A (other       than subsections (a) and (b)) shall apply to a civil money       penalty under this subparagraph in the same manner as such       provisions apply to a penalty or proceeding under section       1128A(a).        ``(6) Definitions.--In this subsection:        ``(A) Rebatable single-dose vial drug.--The term `rebatable       single-dose vial drug' means a single source drug or       biological (as defined in section 1847A(c)(6)(D)) paid for       under this part and furnished on or after January 1, 2020,       from a single-dose vial.        ``(B) Unit.--The term `unit' has the meaning given such       term in section 1847A(b)(2)(B).''.        (b) Collection of Coinsurance Only for Portion of Rebatable       Single-dose Vial Drug Administered.--Section 1833(a) of the       Social Security Act (42 U.S.C. 1395l) is amended--        (1) in subsection (a)(1)(S), by inserting subject to       subsection (cc), before with respect to; and        (2) by adding at the end the following new subsection:        ``(cc) Collection of Coinsurance Only for Portion of       Rebatable Single-dose Vial Drug Administered.--When       processing a claim for a rebatable single-dose vial drug (as       defined in section 1834(w)(6)), the Secretary, acting through       the relevant medicare administrative contractor with respect       to such claim, shall only collect coinsurance from a       beneficiary, taking into account any coverage under a       Medicare supplemental policy certified under section 1882 or       any other supplemental insurance coverage of the beneficiary,       with respect to the portion of the drug administered (as       indicated by the J-portion of the claim for the drug used as       of the date of enactment of this subsection, or any successor       code that includes such data as determined appropriate by the       Secretary), in an amount equal to 20 percent of the amount of       payment that would be made if payment for the claim was based       only on the portion of the drug administered (as so       indicated). Nothing in the preceding sentence shall affect       the amount paid to the provider of services or supplier with       respect to the drug under this part (as determined based on       the total amount of the drug for which the claim was       submitted, including the portion of the drug administered and       the portion discarded, as indicated by the J-portion of the       claim and the JW modifier, respectively, used as of such date       of enactment or any successor codes that include such data as       determined appropriate by the Secretary).''                            ____________________     Mr. President, I ask unanimous consent that the text of  the bill be printed in the Record.   There being no objection, the text of the bill was ordered to be  printed in the Record, as follows:                                   S. 551         Be it enacted by the Senate and House of Representatives of       the United States of America in Congress assembled,       SECTION 1. SHORT TITLE.         This Act may be cited as the ``Recovering Excessive Funds       for Unused and Needless Drugs Act of 2019'' or the ``REFUND       Act of 2019''.       SEC. 2. REQUIRING MANUFACTURERS OF CERTAIN SINGLE-DOSE VIAL                     DRUGS PAYABLE UNDER PART B OF THE MEDICARE                     PROGRAM TO PROVIDE REBATES WITH RESPECT TO                     DISCARDED AMOUNTS OF SUCH DRUGS.         (a) In General.--Section 1834 of the Social Security Act       (42 U.S.C. 1395m) is amended by adding at the end the       following new subsection:        ``(w) Rebate for Certain Discarded Single-dose Vial       Drugs.--        ``(1) In general.--The manufacturer (as defined in section       1847A(c)(6)(A)) of a rebatable single-dose vial drug       furnished in a calendar quarter shall, not later than 30 days       after the date of receipt of information described in       paragraph (2)(A)(iii) with respect to such quarter, provide       to the Secretary a rebate that is equal to the amount       specified in paragraph (3) for such drug for such quarter.        ``(2) Secretarial duties.--        ``(A) In general.--For each calendar quarter, the Secretary       shall, with respect to a rebatable single-dose vial drug of a       manufacturer furnished during such quarter--        ``(i) require, through use of a modifier such as the JW       modifier used as of the date of enactment of this subsection       (or any such successor code that includes such data as       determined appropriate by the Secretary), an indication on a       claim for such drug of the amount of such drug that was       discarded after such drug was furnished, if any;        ``(ii) determine the rebatable amount (as defined in       subparagraph (B)) with respect to such drug; and        ``(iii) not later than 60 days after the end of such       quarter, provide to such manufacturer notice of--         ``(I) the total number of units of such drug discarded       during such quarter (as determined by the Secretary based on       the aggregate rebatable amount (as so defined) with respect       to such drug for such quarter), if any; and        ``(II) the rebate amount specified in paragraph (3) for       such drug and such quarter.         ``(B) Rebatable amount.--The term `rebatable amount' means,       with respect to a rebatable single-dose vial drug of a       manufacturer furnished during a quarter, 90 percent of the       amount (if any) of such drug that was discarded as indicated       pursuant to subparagraph (A)(i).        ``(3) Rebate amount.--The amount of the rebate specified in       this paragraph is, with respect to a rebatable single-dose       vial drug of a manufacturer furnished in a calendar quarter,       an amount equal to the product of--        ``(A) the total number of units of such drug discarded       during such quarter as determined under paragraph       (2)(A)(iii)(I); and        ``(B) the lesser of--        ``(i) the average sales price (as defined in section       1847A(c)(1)) for a unit of such drug for such quarter (or, in       the case of a drug subject to an agreement with such       manufacturer under section 340B of the Public Health Service       Act, the price for a unit of such drug for such quarter under       such agreement); or        ``(ii) the wholesale acquisition cost (as defined in       section 1847A(c)(6)(B)) for a unit of such drug.        ``(4) Rebate deposits.--Amounts paid as rebates pursuant to       paragraph (1) shall be deposited into the Federal       Supplementary Medical Insurance Trust Fund established under       section 1841.        ``(5) Enforcement.--        ``(A) Audits.--Each manufacturer of a rebatable single       dose-vial drug that is required to provide a rebate under       this subsection shall be subject to periodic audit with       respect to such drug and such rebates by the Secretary.        ``(B) Civil money penalty.--        ``(i) In general.--The Secretary shall impose a civil money       penalty on a manufacturer of a rebatable single dose-vial       drug who has failed to comply with the requirement under       paragraph (1) for such drug for a calendar quarter in an       amount the Secretary determines is commensurate with the sum       of--         ``(I) the amount that the manufacturer would have paid       under such paragraph with respect to such drug for such       quarter; and        ``(II) 25 percent of such amount.         ``(ii) Application.--The provisions of section 1128A (other       than subsections (a) and (b)) shall apply to a civil money       penalty under this subparagraph in the same manner as such       provisions apply to a penalty or proceeding under section       1128A(a).        ``(6) Definitions.--In this subsection:        ``(A) Rebatable single-dose vial drug.--The term `rebatable       single-dose vial drug' means a single source drug or       biological (as defined in section 1847A(c)(6)(D)) paid for       under this part and furnished on or after January 1, 2020,       from a single-dose vial.        ``(B) Unit.--The term `unit' has the meaning given such       term in section 1847A(b)(2)(B).''.        (b) Collection of Coinsurance Only for Portion of Rebatable       Single-dose Vial Drug Administered.--Section 1833(a) of the       Social Security Act (42 U.S.C. 1395l) is amended--        (1) in subsection (a)(1)(S), by inserting subject to       subsection (cc), before with respect to; and        (2) by adding at the end the following new subsection:        ``(cc) Collection of Coinsurance Only for Portion of       Rebatable Single-dose Vial Drug Administered.--When       processing a claim for a rebatable single-dose vial drug (as       defined in section 1834(w)(6)), the Secretary, acting through       the relevant medicare administrative contractor with respect       to such claim, shall only collect coinsurance from a       beneficiary, taking into account any coverage under a       Medicare supplemental policy certified under section 1882 or       any other supplemental insurance coverage of the beneficiary,       with respect to the portion of the drug administered (as       indicated by the J-portion of the claim for the drug used as       of the date of enactment of this subsection, or any successor       code that includes such data as determined appropriate by the       Secretary), in an amount equal to 20 percent of the amount of       payment that would be made if payment for the claim was based       only on the portion of the drug administered (as so       indicated). Nothing in the preceding sentence shall affect       the amount paid to the provider of services or supplier with       respect to the drug under this part (as determined based on       the total amount of the drug for which the claim was       submitted, including the portion of the drug administered and       the portion discarded, as indicated by the J-portion of the       claim and the JW modifier, respectively, used as of such date       of enactment or any successor codes that include such data as       determined appropriate by the Secretary).''                            ____________________   